Global Ph 3 Clinical Trial for Cholangiocarcinoma Authorized in the EU and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by EMA March 19, 2024
FDA clears INDs for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b March 19, 2024
FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy March 19, 2024
New clinical data from 2L ONSEMBLE trial provides further evidence of the efficacy of onvansertib + FOLFIRI/bev in bev naïve RAS-mutated mCRC patients March 12, 2024
Global Ph 3 Trial for Cholangiocarcinoma Authorized in the EU and Orphan Drug Designation for Tinengotinib Granted by EMA March 12, 2024
DURIPANC Ph 1b/2 clinical trial of Ampligen with Imfinzi for the treatment of pancreatic cancer opened for enrollment and enrolled first subject March 4, 2024
BLA for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA March 4, 2024
Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA February 26, 2024
US regulatory approval received to start pancreatic cancer Ph IIb trial with nadunolimab February 26, 2024
First Refractory Gastric Cancer Patient Dosed in Ph 2 Trial with Allogeneic INKT Cell Therapy and Botensilimab and Balstilimab February 26, 2024
First Subject Dosed in Ph 1b/2 Study of Ampligen® + Imfinzi for the Treatment of Pancreatic Cancer February 26, 2024
Immune-Onc Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate IO-108 in Ph 1b/2 Study for 1L Treatment of HCC February 26, 2024
US FDA approval of Onivyde® (Irinotecan Liposome Injection) + NALIRIFOX for 1L mPDAC triggers a $225M milestone payment from Ipsen to Merrimack February 26, 2024
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash February 26, 2024
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program February 26, 2024
FDA accepts Supplemental NDA for KRAZATI® (adagrasib) – Cetuximab combo for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or mCRC February 26, 2024
Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolisation January 23, 2024
Data from Ph 1b Study of Quemliclustat-Based Regimens Showed Promising OS in Treatment-Naïve Metastatic Pancreatic Cancer January 23, 2024
